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Clozapine treatment may have beneficial effects on behavioural outcomes in psychotic 
disorders, including violent offending. Although clozapine and other antipsychotics have been 
linked to lower levels of violent behaviour, these have been primarily in small selected 
samples, and population-based estimates have been limited and imprecise.  
We aimed to assess the effect of clozapine treatment on the rate of violent and non-violent 
offending. We carried out a within-person mirror image study of the Swedish population based 
on linked prescription, hospitalization, and sociodemographic registers. Outcomes were 
violent, non-violent, and overall offences occurring before and after clozapine, or olanzapine, 
initiation. Comparison of effects of clozapine and olanzapine on key variables was modelled 
with interaction terms. We found that periods of mirror image observation time of with 
clozapine treatment were associated with a much lower rate of violent offending compared to 
periods before treatment (rate ratio (RR)=0.13(95% confidence interval (CI): 0.05, 0.34). 
Reductions in non-violent offences were smaller in magnitude (RR: 0.37, 95%CI: 0.17, 0.80). 
There was a statistically greater rate reduction effect on violent offences for clozapine, than 
olanzapine (rate ratio for interaction=4.84, 95%CI: 1.56, 14.86, p=0.002). Statistically greater 
rate reductions for violent offences for clozapine compared to olanzapine were noted in those 
with admission for any substance use disorder, including those with alcohol use- and 
cannabis use- disorders. In patients with psychotic disorders, clozapine treatment is 
associated with a lower rate of violent offending compared to olanzapine. Clozapine may 




Clinical management of psychotic disorders typically involves a combination of psychological 
and pharmacological therapy, with the aim of eliminating or limiting symptoms and optimizing 
functioning1. However, violent offending is also an important adverse outcome in psychotic 
disorders2, and is more common in patients diagnosed with psychotic disorders compared to 
the general population3. Psychotic Patients with psychotic disorders patients are frequently 
often inconsistently intermittently treated4, and studies suggest violence is higher in untreated 
patients5.  
 
Some studies have reported lower levels of violence in people treated with antipsychotics, 
particularly second generation drugs6, 7, and especially clozapine8, 9. Such observations are 
complicated by the strong possibility of confounding by indication10. Firstly, a violent episode 
may trigger a psychiatric evaluation, and the initiation of treatment. Secondly, given that 
clozapine requires a commitment by the patient to accept oral medication and frequent blood 
tests, it may be that people who are prescribed clozapine are systematically different from 
those prescribed other treatments in ways that mean that the simple comparison of violence 
occurrence between groups may not be valid.  
 
Accumulating evidence continues to support the clinical effectiveness of clozapine on 
symptoms and hospital use in treatment refractory schizophrenia11, 12. National registers 
linked to prescribing information have clarified the real world effectiveness of antipsychotic 
drugs for a range of outcomes13, 14. However, identifying convictions for violent behaviour from 
national registers is not straightforward. A single conviction may refer to a mixture of separate 
constituent offences, some of which may be violent, and others non-violent; for example, a 
person may be convicted for a combination of theft, assault, and a drug-related offence. 
Fazel15 reported that antipsychotic treatment reduced violent convictions (i.e. convictions for 
offences where at least one offence was violent) in a Swedish population cohort, comparing 
periods of time on treatment with time off treatment, over a three-year period. Effect estimates 
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for clozapine were under-powered in the Fazel study to investigate clozapine, and focused on 
a conviction outcome, rather than on idivdual ofences whic comprised convictions. Furthermore, xplanations for any efct of clozapine tratment on ofending rate have rarely ben examined16. One posibilty isthat he fect ismediated by drug and alcohol dependence. Dependence on alcohol and ilcit substances icommon i schizophrenia17, common i treatment resitance18, and may reduce as  result of clozapine tratment19, 20– howevr, no studies have asesed whether fects of clzapine tratment on violence might be xplained in part by amelioration of dependence.  
 
In this paper, we address these issues by (a) considering occurrence of violent offending in 
people treated for psychotic disorders with clozapine, comparing equal time periods before 
initiation with periods of time after, (b) test whether any effect of clozapine on violent offending 
is greater than that expected of a general antipsychotic effect, by comparing the effect of 
clozapine to that of olanzapine, the most commonly prescribed antipsychotic drug in Sweden, 
and (c) assessing violent and non-violent offences separately. We draw upon registry data on 
clozapine and olanzapine prescriptions in Sweden, linking it with national data on convictions 
to identify violence-related outcomes. Our analysis is within-subject i.e. all comparisons made 




Using a within-subject design, also known as a mirror-image model, we compared the rate of 
offences during treatment with clozapine or olanzapine with periods of time of equal duration 




The unique Swedish personal identity number21 was used to link information from the 
following population-based registers:  
 
1. The Causes of Death Register, comprising information on all deaths of Swedish residents 
since 1952 with causes of death coded according to the International Classification of 
Diseases (ICD)22,  
2. The National Patient Register (NPR), including all individuals admitted to psychiatric or 
general hospitals, with complete coverage for all in-patient care since 1987, and for 
specialized hospital-based (as opposed to primary care-based) out-patient care since 200623, 
3. The Total Population Register, containing comprehensive information on age, sex, place of 
residence, and other relevant demographic characteristics24 on Swedish people,  
4. The Longitudinal Integration Database for Health Insurance and Labour Market Studies 
(LISA), which integrates existing data from the labour market, educational and social 
sectors25, 
5. The Register of Court Conviction, containing information on all court convictions and offences 
in Sweden for individuals 15 years of age or older since 197326 , and  
6. Lastly, the Prescribed Drug Register27, which contains patient identities for all dispensed 
prescribed drugs to the entire Swedish population since July 1st 2005, classified using the 





Derivation of study population 
 
All prescriptions  for clozapine and olanzapine (ATC-code N05AH02 and ATC-code N05AH03 
respectively) registered from July 2005 until June 2012 were retrieved, excluding individuals 
who were prescribed both medicines, either concurrently or at different points in this period. 
Those that had a start date during 2005 were excluded, as a conservative measure to ensure 
the only new initiations of clozapine treatment were included. Of these, all Swedish people 
born 1955-1988 who had a first prescription of clozapine or olanzapine between January 1, 
2006 and December 31, 2010 were kept. Those without a psychotic disorder or 
schizoaffective disorder (ICD-10 F20-F29) were further excluded (257 people).  
 
In order to be confident that individuals included in the analysis were exposed to sustained 
periods of treatment, we limited our study to individuals treated with each drug for a minimum 
of 8 weeks. We identified 1176 people living in Sweden who were initiated on clozapine 
during the study period, and 4527 who were initiated on olanzapine. Among those prescribed 
clozapine, 1126 received more than one prescription of clozapine, of which 1086 had 
complete information on observation time (40 had missing data on the end of observation 
time, as defined below), of which 1004 were treated with clozapine for longer than 8 weeks 
and were included in the analysis. Among those prescribed olanzapine, 3967 had more than 
one olanzapine prescription, of which 3238 had valid complete information on observation 
times (729 had missing data on the end of observation time, as defined below), of which 2258 
were continuously treated for 8 weeks or longer. Thus, our analysis was based on 1004 
subjects treated with clozapine and 2258 subjects treated with olanzapine. To evaluate any 
influence of the 8 weeks criterion on our results, we inspected data on individuals prescribed 
each drug for less than 8 weeks. 
 
Definition of observation time in subjects: 
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Data on convictions were collected for individuals in the study population described above, for 
(a) as long as possible following initiation of the drug, and (b) for a period of time of equal 
duration prior to the initiation of the drug. 
 
Firstly, the “forward” observation time at risk for these outcomes was defined, using the Total 
Population register, as the elapsed number of days from the date of initiation of the drug to 
either: 
 
1. the discontinuation date for the drug (defined as the last date of prescribed medication where 
this occurred prior to a period of 6 months without a prescription for the drug, or without an 
inpatient psychiatric admission during this period), or 
2. date of emigration, or 
3. date of death, or 
4. date of the end of the study period, which was 31st December 2011. 
 
Secondly, having identified the forward observation time at risk, a backward observation time 
was defined for each subject of the same length. In the event that the backward observation 
time extended to a point before the start of the prescription register, the forward observation 
time was shortened to match the backward observation time. Data on offences were then 
gathered, classified by whether they occurred in the “before” period (prior to initiation of the 
drug) or the “after” period (during drug treatment), within the mirror image observation time.  
 
Measurement of outcomes 
 
Dates of all offences for which there were convictions during the mirror image observation 
time (1st January 2006 – 31st December 2011) were collected for all study participants. We 
classified offences into violent offences and non-violent offences. Violent offences included 
manslaughter, homicide, assault, gross assault, assault on a public official, arson, murder, 
unlawful threat, sexual crimes, crimes involving a weapon, cruelty to an animal, and 
infanticide. A full list of offences, and their classification into ‘violent’ and ‘non-violent’, is 
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displayed in table 1. Counts for violent and non-violent offences, and overall offences, were 
generated based on this information.  
 
Measurement of covariates 
 
Owing to the within-subject design, account was taken of characteristics that did not change 
over time: data on these were available for gender, age, highest educational attainment 
(categorized into compulsory education (≤9 years), “high school” education (10- 12 years), 
and University or higher (≥13 years)), born in Sweden, the age and year of psychotic 
disorders diagnosis, and the age and date of drug initiation. We also considered 
characteristics that changed over time: employment status, presence of salary (as a binary 
variable yes/no), social salary (salary derived from social benefits, in quintiles), living in one of 
top three biggest cities (Stockholm, Gothenburg or Malmö), and the presence of 
unemployment benefit (a state benefit specifically for unemployment). This information was 
available 2 years before drug start, and at the time of drug start, and was used to measure 
characteristics in the before and during observation periods within the mirror image 
observation time, respectively. To examine the effect of clozapine on offending in individuals 
with psychotic disorders comorbid with other mental and behavioral disorders, information 
from the National Patient Register was used to classify eligible subjects by whether they had 
one or more admissions at any time for the following reasons: any substance-use disorder, 
alcohol-use disorder, cannabis-use disorder, and sedative-use disorder. The substance use 
disorder category was inclusive of admissions for alcohol (ICD-10 code: F10, ICD-9: 303, 
305A, 291A-291X, ICD-8: 291, 303), cannabis (ICD-10: F12 except for F12.5 and F12.7, ICD-
9: 304D, ICD-8: 304.50), sedatives (ICD-10: F13, ICD-9: 304B, ICD-8: 304.20, 304.30), 
stimulants (ICD-10: F14, F15, ICD-9: 304C, 304E, ICD-8: 304.40, 304.60), and opiates (ICD-
10: F11, ICD-9: 304A, ICD-8: 304.00, 304.10). Information on other mental disorders was 
based on admission diagnoses for mood disorder (ICD-8:296.0, 296.1-296.9; ICD-9: 296.00-
296.16, 311; ICD-10: F30-F39), and anxiety disorders(ICD-8: 300.0-300.9; ICD-9: 300 except 





All analyses were performed in Stata 1428. Sociodemographic characteristics and substance-
related and other comorbidities were described for both drugs and compared using chi-
squared tests. Offence rates were expressed per 100 persons. Owing to large numbers of 
zeroes (i.e. observation periods where no offences occurred), poisson, zero-inflated poisson, 
and zero-inflated binomial regression models were compared on fit, assessed by both the 
Akaike Information Criteria (AIC) and the Bayes Information Criteria (BIC). Zero-inflated 
negative binomial regression models gave best fit, and this model framework, incorporating 
robust standard errors, was retained. Counts of violent, non-violent, and overall offences were 
compared by estimating the main effect (rate ratio) of treatment status with 
clozapine/olanzapine, comparing offence rate before treatment with during treatment. 
Difference in violence-reducing effects between clozapine and olanzapine were estimated by 
including an interaction term for drug (clozapine vs. olanzapine). All covariates were entered 
into zero-inflated negative binomial regression models in order to arrive at an adjusted 
estimate. Given the within-subject design, only time-changing covariates, namely employment 
status, income, residing in one of Sweden’s three biggest cities, and unemployment benefit 
receipt were evaluated as potential confounders, by deriving and adjusting for categorical 
indicators for the before and the during observation period within the mirror image observation 
time. Age and calendar year at drug initiation/psychotic disorders diagnosis, gender, highest 
educational attainment, and whether the person was born in Sweden were not included as 
covariates because they did not vary within subjects. Effects were estimated stratified by 
these variables, and by the presence of admissions for substance use disorders (comprising 
alcohol use-, cannabis use-, sedative use-, stimulant use-, and opiate use-related disorders), 
and the presence of any admissions for mood disorder or anxiety disorder.  
 
Zero-inflated negative binomial models are estimated in two parts29, consisting of a negative 
binomial model, in this study estimating counts of violent offences in patients who offend, 
which was the focus of our analysis. Zero-inflated negative binomial models also estimate a 
logit model, predicting excess zeros, in this study, zeros refer to periods of observation within 
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the mirror image observation time without offences, and we included inflation coefficients for 
age and gender, reflecting that these were the main influences on zero-offending30. The 
negative binomial model also estimates a dispersion parameter, quantifying the extent to 
which variance exceeds that expected under a poisson model. Supplementary analyses 
tested crude and fully adjusted associations stratified by gender (tables S4 and S5), and by 








Table 1 describes the coding of offences into violent and non-violent categories used for this 
study. Table 2 summarises sample characteristics. A total of 2258 people treated with 
olanzapine met criteria for the study, of which 1385 (61.3%) were male, compared to a slightly 
greater proportion in clozapine-treated patients (66.0%, n=1004). More than three-quarters of 
the olanzapine patients were born in Sweden (76.2%), compared to nearly 80% of the 
clozapine group. Treatment for two years or more was more common among clozapine 
subjects than olanzapine (51.4% compared to 31.9%). The prevalence of any admissions for 
substance use disorders was similar between subjects treated with clozapine and with 
olanzapine (clozapine: 32.7%, olanzapine: 32.9%), with similarities in proportion of specific 
substance use disorders between the two groups. Any admission for mood disorder was also 
commoner in the olanzapine group (36.5%, compared to 32.0% in the clozapine group). 
Between treatment groups, there was difference in duration of observation time, with a higher 
proportion of olanzapine patients treated for less than a year, and a higher proportion of 
clozapine patients (about a third) treated for more than three years compared to the 
olanzapine group (around a fifth). There was statistical evidence for differences between 
clozapine and olanzapine treated groups for all covariates included in this study.  
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Table 3 summarises data on offences. Based on 369 offences in the clozapine group, and 
960 offences in the olanzapine group, we estimated a rate reduction of around 75% in the 
clozapine group, and 50% in the olanzapine group with statistical evidence of difference 
between the two drugs (p value for interaction between drug and period of 
observation=0.015). The rate reduction for non-violent offences, comparing before treatment 
to during treatment for clozapine, was 63% after adjustments, compared to 39% for 
olanzapine. For violent offences, the fully adjusted rate reduction for treatment compared to 
before treatment was 87% for clozapine, and 8% for olanzapine (RR for clozapine: 0.13, 
95%CI: 0.05, 0.34, RR for olanzapine: 0.82,95%CI:0.47, 1.43, p value for the interaction 
between drug and period of treatmentobservation: 0.002). In the final adjusted model for 
overall offences, female gender (compared to male gender) predicted zero offences during 
periods of observation (p=0.027), but age did not, and neither gender nor age were 
statistically evidenced predictors of zero counts for non-violent, or overall offences.  
 
Statistical evidence for clozapine effects on violent offending were evident on stratification for 
all selected comorbidities, with the exception of those with a history of sedative- , stimulant-, 
and opiate-use disorders(table 4). Violent offences rate reductions for olanzapine were 
generally lesser in magnitude, with statistical evidence for interaction between drug and 
period of treatment for substance-use disorders, alcohol use disorders, and cannabis use 
disorders. Clozapine treatment was associated with reduced violent offending rate for those 
with any substance use-related disorder (RR:0.07, 95%CI:0.02,0.24), alcohol use disorder 
(RR:0.09, 95%CI:0.02,0.37), cannabis use disorder (RR:0.10, 95%CI: 0.01,0.73), mood 
disorder (RR: 0.36, 95%CI: 0.13,0.99), and anxiety disorder (RR: 0.13, 95%CI: 0.04,0.46), 
with olanzapine associated with reductions in violent offence rate only for those with overall 
substance use disorder (RR: 0.40, 95%CI: 0.19,0.87). For non violent offences, clozapine 
treatment was associated with reduced offence rate in those with opiate use disorder 
(RR:0.05, 95%CI: 0.01, 0.64), and olanzapine was associated with non-violence offence rate 
reductions in those with any substance use disorder (RR:0.58, 95%CI: 0.40,0.83) and alcohol 
use disorder only (RR: 0.60, 95%CI: 0.38,0.96). Both clozapine and olanzapine were was 
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Time-varying characteristics for olanzapine-treated and clozapine-treated subjects are shown 
in table S1 of the supplementary material. The proportion of people working fell slightly for 
subjects treated with both drugs. The presence of salary fell among both the olanzapine 
group (22.7% to 17.8%) and the clozapine group (15.8% to 9.7%). Model estimates from the 
zero prediction part of final models for violent, non-violent and overall offences are displayed 
in table S2 of the Supplementary Material. . Interaction terms from models based on patients 
with comorbidities, and zero-prediction coefficients and dispersion parameters for these 
models, are displayed in table S3. In this paper, final estimates for the effects of clozapine 
and olanzapine on offending, interaction terms and interaction p values are presented in table 
3. Effect estimates and interaction p values for models based only on those with comorbidities 
are presented in table 4. Zero-prediction coefficients and dispersion parameters for violent, 
non-violent and overall offences are presented in table S2. , and table S3 displays interaction 
terms for each comorbidity, and zero-prediction coefficients and dispersion parameters for 
each model. Estimates restricted by gender gave similar results, however among women, 
statistical evidence was insufficient at the 5% alpha level (table S4). Rate reductions were 
less among those with a mirror image observation time of shorter than 3 years (table S5), 
compared to those with a mirror image observation time of greater than 3 years (table S6). No 
violent offences were identified among 190 subjects who were prescribed clozapine for less 
than 8 weeks. Among 492 individuals prescribed clozapine for less than 8 weeks, there were 
no violent offences during the mirror image observation time before initiation, and 4 offences 
in the mirror image observation time following initiation. 
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Summary of findings 
 
In the population of Sweden, clozapine treatment was associated with greater reductions in 
overall and violent offending, but not non-violent offending, compared to olanzapine, the most 
commonly prescribed antipsychotic drug in Sweden. This was not accounted for by 
confounding by time-changing socioeconomic characteristics. There was statistical evidence 
in favour of greater effects for clozapine than olanzapine on violent offending in those with a 
substance disorder, and for those with alcohol use- and cannabis use- disorders specifically. 
In contrast,E effects of clozapine on non-violent offending were statistically similar to 
olanzapine, suggesting that clozapine may offer specific benefits on the risk of violent 
offending in people with psychotic disorders.  
 
Limitations and Strengths 
 
There may be local factors that determine clozapine prescription, and our sample may not be 
representative of clozapine users outside Sweden. Our results, in particular the estimates of 
pre-treatment rate of offences, could have been affected by an underlying trend towards less 
offending in patients with psychotic disorders as they get older, irrespective of how they are 
treated. . Initiation of treatment in some individuals could have occurred as a result of violent 
behaviour, for example triggering arrest and subsequent psychiatric evaluation. We did not 
assess the effect of concurrent medicines in this study, including the effect of concurrent 
treatment with clozapine and olanzapine.. Although data on psychiatric diagnoses was 
comprehensive, misclassification is a possibility. A validation study involving record review of 
admission diagnoses in Sweden suggested good correspondence, with kappa values of 
between 0.74 and 0.7631. Around 85% of patients with an admission diagnosis of 
schizophrenia in Sweden had DSM-IV schizophrenia diagnoses assigned by clinical raters, in 
another study32. However, although register-derived psychiatric diagnoses display reasonable 
correspondence with clinical diagnoses, admission diagnoses of substance use disorders, 
Commented [VB2]: Include gender-specific results 
here 
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may only capture more severe cases of substance misuse; effects identified for clozapine on 
offending in those with this outcome may therefore not be generalizable to those with 
substance use disorders who have not experienced admission for a substance use disorder.   
Although adjustment was made for time-varying covariates, factors such as age, gender, and 
calendar time could not be examined directly, due to the chosen design. Mirror-image studies 
cannot take account of the possible effects of health policy changes on the background rates 
of the outcome. Adjusted estimates should therefore be interpreted with caution33. However, 
we were primarily interested in comparison between clozapine and olanzapine. We think the 
influence of these factors are likely to have been similar between the two treatment groups, 
and therefore unlikely to fully explain differences between olanzapine and clozapine treatment 
observed in this study. We included prescribing data from 2006; having such data prior to 
2006 would have afforded a longer study period, and increased the ability to assess the 
impact on our results of change in underlying offending patterns over time. It is possible that 
predictors of offending that were not accounted for in this study, such as personality disorders 
or cognitive impairment, could have affected our results. We included only patients treated for 
longer than 8 weeks in our analysis – limiting the generalizability of our findings to people 
receiving treatment for at least this length of time. No violent offences occurred in mirror 
image observation times among individuals prescribed clozapine for less than 8 weeks. Prior 
to the availability of inpatient prescription data in 2006, patients may have initiated 
clozapine/olanzapine during an inpatient admission, but received the first recorded 
prescription only after discharge, resulting in a start time for the mirror image observation 
period which was later than the true start time for the drug, and misclassification of time on 
treatment as time off treatment. Any bias introduced by this would likely be towards 
underestimating the effectiveness of both drugs.” 
. 
 
On the other hand, our analysis was based on dates for offences rather than convictions in 
contrast with previous population-based studies, although we did not distinguish among 
offences comprising a conviction, beyond the classification of offences into violent and non-
violent.  Offences data was were taken from a whole population based register of convictions 
Formatted: Font: (Default) Arial, 10 pt
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with effectively total coverage; bias introduced by missing data on convictions is very unlikely. 
We had information on women, in contrast to one previous study on this topic in Sweden15 
that was restricted to men, and had access to enough data on clozapine to arrive at a precise 
estimate of rate reduction of violent offences attributable to clozapine treatment. Information 
on convictions and their aligned offences was from a national register of court proceedings, 
not based on self-report. We studied both overall and violent offences as the outcome. Our 
data were based on dispensed prescriptions for these drugs, and made the assumption that 
dispensing of the drug was equivalent to full adherence, making it analogous to an intention to 




The mechanisms by which psychosis leads to violent behaviours are largely unclear. 
HoweverThe observed, reduction in violent offending rate for both antipsychotic drugs 
indicates that this could be a class effect of antipsychotic drugs as a whole, with clozapine 
being particularly effective, consistent with the superiority of clozapine over other 
antipsychotics in other areas34, 35. Clozapine could improve engagement with healthcare staff, 
social cognition, reduce irritability, improve social and occupational functioning, or effects on 
psychotic symptoms could mediate the effect. Clozapine-treated patients are typically affected 
by more severe illness and more treatment resistant symptoms, and clozapine treatment 
requires greater contact with the mental health system. In this regard, the current study was 
not able to distinguish among possible active components of clozapine treatment in relation to 
offending, including the role of increased contact with the health care system.  One future 
approach to examining this could be to compare clozapine with another treatment that also 
involves increased contact with the health care system, such as long-acting injections (LAI). 
We observed larger rate reductions for clozapine among those with comorbid substance use 
disorders compared to psychotic disorders as a whole, implying that the benefits of clozapine 








There is a consistent observational association between psychotic disorders and violence3. 
Violence risk in psychotic disorders may be related to clinical status36, concurrent substance 
use disorders, or to non-adherence with antipsychotic medication5. Although Swanson et al 6 
found that the violence reducing effects of atypical antipsychotics was greater than for 
typicals, an analysis of CATIE trial data by the same investigators indicated that violence 
reduction in newer antipsychotics was not significantly greater than for perphenazine, a 
traditional typical antipsychotic drug37. Convictions may happen a significant period of time 
after the offences themselves, leading to bias in effect estimates; the present study analysed 
date information on offences within convictions, and therefore benefited from greater 
statistical power. In contrast to previous work, the present study also adjusted for 
employment, salary presence, unemployment benefits, and place of residence as time-
changing covariates that may have had an influence both on prescription of each drug and 
the offending outcome. Typically, measurement of violence in pharmacological studies has 
been done by independent observers using rating scales; few studies have used 
legal/administrative outcomes such as criminal conviction5. Stevens et al report a randomised 
controlled trial showing no effect of assertive specialized treatment on offending in first 
episode psychosis patients, suggesting the need for specific, rather than universal 
interventions for violence reduction38.  
 
How our results fit in 
 
As far as we are aware, this is the first report of violence reducing effects of clozapine in a 
population-based sample of both men and women and in a within-subject observational 
design. We also found an (albeit weaker) effect for olanzapine, in accordance with some 
previous work6. Our results suggest that the effects are independent of socioeconomic factors 









We found strong statistical evidence for a violence reducing effect of clozapine in whole 
population data from Sweden that was larger in magnitude than olanzapine. Clozapine may 
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Table 1. Coding of offences used in this study 






Cruelty to animals 
Sexual crimes 
Murder by carelessness 
Unlawful threat 
Weapon-related crime 





























Table 2. Description of clozapine(n=1004) and olanzapine 
(n=2256) and samples by non-time changing characteristics, 
based on prescription registers for the whole of Sweden, 
reflecting first withdrawal of each drug between 1st January 
2006 to 31st December 2010 
 Clozapine Olanzapine 
 Count(%) Count (%) 
Year of treatment start   
2006 204 (20.32) 664 (29.41) 
2007 194 (19.32) 490 (21.7) 
2008 201 (20.02) 360 (15.94) 
2009 213 (21.22) 372 (16.47) 
2010 192 (19.12) 372 (16.47) 
Gender     
Male 663 (66.04) 1385 (61.34) 
Female 341 (33.96) 873 (38.66) 
Born in Sweden 797 (79.38) 1721 (76.22) 
Duration of treatment    
8 weeks-1 year 224 (22.31) 1001 (44.33) 
1 year – 3 years 446 (44.42) 788 (34.90) 
3 years or more 334 (33.27) 469 (20.77) 
Educational attainment at 
treatment start 
    
≤ 9 years 343 (34.16) 702 (31.09) 
10-12 years 576 (57.37) 1317 (58.33) 
University or higher 53 (5.28) 172 (7.62) 
Missing  32 (3.19) 67 (2.97) 
Age at drug start(years)     
18<28 206 (20.52) 295 (13.06) 
28<38 331 (32.97) 578 (25.6) 
38<48 319 (31.77) 920 (40.74) 
48<58 148 (14.74) 465 (20.59) 
Start periods     
Before 2007 398 (39.64) 1154 (51.11) 
After 2008 606 (60.36) 1104 (48.89) 
Period of psychotic disorders 
diagnosis 
    
1970-1982 34 (3.39) 102 (4.52) 
1983-1991 137 (13.65) 295 (13.06) 
1992-2001 291 (28.98) 585 (25.91) 
2002- 542 (53.98) 1276 (56.51) 
Age at psychotic disorders 
diagnosis 
    
18<28 536 (53.39) 861 (38.13) 
28<38 310  (30.88) 763 (33.79) 
38<48 141  (14.04) 527 (23.34) 
48<58 17  (1.69) 107 (4.74) 
 
Table 3. Descriptive data (absolute counts and rate of offences per 1000 person years of observation) for overall, violent, and 
non-violent offences for olanzapine (n=2258) and clozapine treatment (n=1004). Also shown are crude and adjusted offence 
(overall, non-violent, and violent) rate ratios with 95% confidence intervals for during vs before treatment with clozapine and 
olanzapine.  
 Clozapine Olanzapine Interaction term P value for 
interaction  
Total number of violent offences 103 506    
Individuals with any violent offence(percentage 
of the overall treatment group) 
63(6.27) 144(6.38)   
Number of violent offences before treatment 
(rate) 
96(74.41) 376(95.71)   
Number of violent offences during treatment 
(rate) 
7(5.43)  130(33.09)   
Effect of drug on violent offence rate RR  95% CI RR 95% CI   
Crude 0.07 0.03 , 0.18 0.35 0.20 , 0.61   
Fully adjusteda 0.13 0.05 , 0.34 0.82 0.47 , 1.43 4.82(1.56,14.86) p=0.002 
Total number of non-violent offences 222 507   
Individuals with any non-violent 
offence(percentage of the overall treatment 
group) 
69(6.87) 193(8.55)   
Number of non-violent offences before 
treatment (rate) 
161(124.79) 326(82.99)   
Number of non-violent offences during 
treatment (rate) 
61(47.28) 181(46.07)   
Effect of drug on non-violent offence rate RR 95% CI RR 95% CI   
Crude 0.38 0.17 ,0.83 0.56 0.40 0.76   
Fully adjusteda 0.37 0.17 ,0.80 0.61 0.44 ,0.86 1.66(0.68,4.04) p=0.263 
Total number of overall offences 369 960   
Individuals with any overall offence(percentage 
of the overall treatment group) 
128(12.75) 304(13.46)   
Number of overall offences before treatment 
(rate) 
295(122.69) 635(161.64)   
Number of overall offences during treatment 
(rate) 
74(30.78) 325(82.73)   
Effect of drug on overall offence rate  RR 95% CI RR 95% CI   
Crude 0.25 0.12 ,0.51 0.51 0.12 ,0.51   
Fully adjusteda 0.24 0.12 ,0.48 0.62 0.45 , 0.85 2.55(1.20,5.44) p=0.015 
Rate ratios were estimated from zero-inflated negative binomial regression models with offence rate as the dependent variable 
and period of observation (dichotomised into before treatment and during treatment), as the main independent variable of interest. 
Models took account of clustered before and during treatment data within individuals. Model estimates for zeroes are presented in 
table 1 of the Supplementary material.  















Table S1. Description of time-changing variables for each drug. “Before” variables reflect 2 
years before start date of the drug, and “during” values reflect characteristics at the time of 
drug start.  
 Clozapine Olanzapine  
Before (%) During (%) Before (%) During (%) 
Employment status      
    
Working 88 (8.76) 69 (6.87) 336 (14.88) 287 (12.71) 
Not working but 
paying tax 
76 (7.57) 36 (3.59) 207 (9.17) 139 (6.16) 
Not working, not 
paying tax 
829 (82.57) 897 (89.34) 1677 (74.27) 1821 (80.65) 
Missing 11 (1.10) 2 (0.20) 38 (1.68) 11 (0.49) 
Salary presence         
No 834 (83.07) 905 (90.14) 1708 (75.64) 1846 (81.75) 
Yes 159 (15.84) 97 (9.66) 512 (22.67) 401 (17.76) 
Missing 11 (1.10) 2 (0.20) 38 (1.68) 11 (0.49) 
Social income 
(quintiles)  
        
1 185 (18.43) 158 (15.74) 331 (14.66) 279 (12.36) 
2 193 (19.22) 205 (20.42) 321 (14.22) 358 (15.85) 
3 218 (21.71) 248 (24.70) 526 (23.29) 556 (24.62) 
4 200 (19.92) 183 (18.23) 588 (26.04) 588 (26.04) 
5 197 (19.62) 208 (20.72) 454 (20.11) 466 (20.64) 
Missing 11 (1.10) 2 (0.20) 38 (1.68) 11 (0.49) 
Urban residence         
No 744 (74.10) 760 (75.70) 1673 (74.09) 1687 (74.71) 
Yes 249 (24.80) 242 (24.10) 547 (24.22) 560 (24.80) 
Missing 11 (1.10) 2 (0.20) 38 (1.68) 11 (0.49) 
Total 1004 (100) 1004 (100) 2258 (100) 2258 (100) 
McNemar test comparisons for before compared to during treatment, for employment and for 
the presence of salary were <0.001 for both clozapine, and olanzapine. For social income, p 
values for McNemar test were 0.246 for clozapine and <0.001 for olanzapine. P values for 
comparison of urban residence was 0.632 for clozapine, and 0.827 for olanzapine 
 
Table S2. Final fully adjusted model estimates predicting zero offences, from zero-inflated negative binomial regression for violent, non-violent and overall 
offences 




















Female gender 2.31 0.027 0.26 4.36 12.71 0.062 -0.61 26.03 15.21 0.207 -8.42 38.85 
Age in years 0.06 0.083 -0.01 0.12 0.04 0.511 -0.07 0.15 0.04 0.099 -0.01 0.10 





Table S3. Descriptive data (absolute counts and rates per 1000 person years) for overall, violent, and non-violent offences for 
men with olanzapine (n=1385) and clozapine treatment (n=413). Also shown are crude and adjusted offence (overall, non-
violent, and violent) rate ratios with 95% confidence intervals for during vs before treatment with clozapine and olanzapine.  
 Clozapine Olanzapine Interaction term P value for 
interaction  
Total number of violent offences 88 411   
Individuals with any violent offence(percentage 
of the overall treatment group) 
53(12.83) 123(8.88)   
Number of violent offences before treatment 
(rate) 
85(81.76) 308(161.63)   
Number of violent offences during treatment 
(rate) 
3(2.89) 103(54.05)   
Effect of drug on violent offence rate RR  95% CI RR 95% CI   
Crude 0.04 0.01 ,0.12 0.34 0.20 ,0.57   
Fully adjusteda 0.03 0.01 ,0.11 0.38 0.21 ,0.69 11.03(3.01,40.35) <0.001 
Total number of non-violent offences 172 375   
Individuals with any non-violent 
offence(percentage of the overall treatment 
group) 
50(12.11) 152(10.97)   
Number of non-violent offences before 
treatment (rate) 
126(121.20) 240(96.35)   
Number of non-violent offences during 
treatment (rate) 
46(44.25) 135(54.20)   
Effect of drug on non-violent offence rate       
Crude 0.37 0.15 ,0.91 0.56 0.40 ,0.80   
Fully adjusteda 0.36 0.14 ,0.89 0.64 0.43 ,0.95 1.78(0.61,5.22) 0.288 
Total number of overall offences 298 744   
Individuals with any overall offence(percentage 
of the overall treatment group) 
101(24.46) 250(18.05)   
Number of overall offences before treatment 
(rate) 
243(149.94) 498(199.93)   
Number of overall offences during treatment 
(rate) 
55(33.94) 246(98.76)   
Effect of drug on overall offence rate  RR 95% CI RR 95% CI   
Crude 0.23 0.10 ,0.52 0.49 0.36 ,0.68   
Fully adjusteda 0.22 0.10 ,0.50 0.54 0.37 ,0.78 2.45(0.95,6.32) 0.064 
Rate ratios were estimated from zero-inflated negative binomial regression models with offence rate as the dependent variable 
and period of observation within mirror image observation time (dichotomised into before treatment and during treatment), as the 
main independent variable of interest. Models took account of clustered before and during treatment data within individuals.  






Table S4. Descriptive data (absolute counts and rates per 1000 person years) for overall, violent, and non-violent offences for 
women with olanzapine (n=873) and clozapine treatment (n=105). Also shown are crude and adjusted offence (overall, non-
violent, and violent) rate ratios with 95% confidence intervals for during vs before treatment with clozapine and olanzapine.  
 Clozapine Olanzapine Interaction term P value for 
interaction  
Total number of violent offences 15 95   
Individuals with any violent offence(percentage 
of the overall treatment group) 
10(9.52) 21(2.41)   
Number of violent offences before treatment 
(rate) 
11(43.89) 68(56.39)   
Number of violent offences during treatment 
(rate) 
4(15.96) 27(22.39)   
Effect of drug on violent offence rate RR  95% CI RR 95% CI   
Crude 0.38 0.10 ,1.46 0.41 0.07 ,2.38   
Fully adjusteda 0.34 0.08 ,1.39 0.55 0.09 ,3.30 1.63 (0.16, 16.61) 0.681 
Total number of non-violent offences 50 132   
Individuals with any non-violent 
offence(percentage of the overall treatment 
group) 
19(18.10) 41(4.70)   
Number of non-violent offences before 
treatment (rate) 
35(139.66) 86(59.83)   
Number of non-violent offences during 
treatment (rate) 
15(59.85) 46(32.00)   
Effect of drug on non-violent offence rate       
Crude 0.44 0.09 ,2.04 0.54 0.26 ,1.08   
Fully adjusteda 0.40 0.08 ,2.04 0.60 0.32 ,1.11 1.51(0.26,8.78) 0.648 
Total number of overall offences 71 216   
Individuals with any overall offence(percentage 
of the overall treatment group) 
27(25.71) 54(6.19)   
Number of overall offences before treatment 
(rate) 
52(66.35) 137(95.30)   
Number of overall offences during treatment 
(rate) 
19(24.24) 79(54.96)   
Effect of drug on overall offence rate        
Crude   0.37 0.10 ,1.39 0.58 0.27 ,1.27   
Fully adjusteda 0.35  0.09 ,1.38 0.55  0.30 ,1.01 1.56(0.35,6.96) 0.558 
Rate ratios were estimated from zero-inflated negative binomial regression models with offence rate as the dependent variable 
and period of observation within mirror image observation time (dichotomised into before treatment and during treatment), as the 
main independent variable of interest. Models took account of clustered before and during treatment data within individuals.  





Table S5. Descriptive data (absolute counts and rates per 1000 person years) for overall, violent, and non-violent offences for 
women with olanzapine (n=1789) and clozapine treatment (n=333) among those with mirror image observation times of less than 
three years. Also shown are crude and adjusted offence (overall, non-violent, and violent) rate ratios with 95% confidence 
intervals for during vs before treatment with clozapine and olanzapine.  
 Clozapine Olanzapine Interaction term P value for 
interaction  
Total number of violent offences 28 269   
Individuals with any violent offence(percentage 
of the overall treatment group) 
21(6.31) 90(5.03)   
Number of violent offences before treatment 
(rate) 
24(49.15) 164(11.43)   
Number of violent offences during treatment 
(rate) 
4(8.19) 105(70.70)   
Effect of drug on violent offence rate       
Crude 0.27 0.07 ,0.99 1.14 0.58 ,2.23   
Fully adjusteda 0.30 0.06 ,1.44 0.90 0.49 ,1.66 3.02(0.57,16.09) 0.194 
Total number of non-violent offences 74 307   
Individuals with any non-violent 
offence(percentage of the overall treatment 
group) 
31(9.31) 130(7.27)   
Number of non-violent offences before 
treatment (rate) 
51(104.45) 183(98.63)   
Number of non-violent offences during 
treatment (rate) 
23(47.10) 124(66.83)   
Effect of drug on non-violent offence rate       
Crude 1.20 0.28 ,5.22 0.91 0.59 ,1.39   
Fully adjusteda 1.01 0.19 5.49 1.03 0.72 ,1.49 1.02(0.19,5.52) 0.980 
Total number of overall offences 120 560   
Individuals with any overall offence(percentage 
of the overall treatment group) 
51(15.32) 203(11.35)   
Number of overall offences before treatment 
(rate) 
90(94.65) 330(178.13)   
Number of overall offences during treatment 
(rate) 
30(31.55) 230(124.02)   
Effect of drug on overall offence rate        
Crude 0.62 0.06 ,6.81 1.10 0.73 ,1.65   
Fully adjusteda 0.51 0.06 ,4.50 1.12 0.75 ,1.68 2.20(0.24,19.80) 0.482 
Rate ratios were estimated from zero-inflated negative binomial regression models with offence rate as the dependent variable 
and period of observation within mirror image observation time (dichotomised into before treatment and during treatment), as the 
main independent variable of interest. Models took account of clustered before and during treatment data within individuals.  





Table S6. Descriptive data (absolute counts and rates per 1000 person years) for overall, violent, and non-violent offences for 
women with olanzapine (n= 469) and clozapine treatment (n= 185) among those with mirror image observation times of three 
years or greater. Also shown are crude and adjusted offence (overall, non-violent, and violent) rate ratios with 95% confidence 
intervals for during vs before treatment with clozapine and olanzapine.  
 Clozapine Olanzapine Interaction term P value for 
interaction  
Total number of violent offences 75 237   
Individuals with any violent offence(percentage 
of the overall treatment group) 
42(22.70) 54(11.51)   
Number of violent offences before treatment 
(rate) 
72(89.79) 212(130.35)   
Number of violent offences during treatment 
(rate) 
3(3.74) 25(15.37)   
Effect of drug on violent offence rate       
Crude 0.04 0.01 ,0.14 0.12 0.05 ,0.26   
Fully adjusteda 0.04 0.01 ,0.12 0.13 0.06 ,0.28 3.64(0.93,14.27) 0.063 
Total number of non-violent offences 148 200   
Individuals with any non-violent 
offence(percentage of the overall treatment 
group) 
38(20.54) 63(13.43)   
Number of non-violent offences before 
treatment (rate) 
110(137.17) 143(68.98)   
Number of non-violent offences during 
treatment (rate) 
38(47.39) 57(27.50)   
Effect of drug on non-violent offence rate       
Crude 1.29 0.49 ,3.36 0.69 0.33 ,1.47   
Fully adjusteda 1.20 0.48 ,3.04 0.78 0.40 ,1.55 0.65(0.18,2.39) 0.517 
Total number of overall offences 249 400   
Individuals with any overall offence(percentage 
of the overall treatment group) 
77(41.62) 101(21.54)   
Number of overall offences before treatment 
(rate) 
205(141.04) 305(147.12)   
Number of overall offences during treatment 
(rate) 
44(30.27) 95(45.83)   
Effect of drug on overall offence rate        
Crude 0.91 0.18 ,4.59 0.60 0.34 ,1.04   
Fully adjusteda 0.82 0.16 ,4.13 0.66 0.38 ,1.14 0.81(0.13,4.88) 0.818 
Rate ratios were estimated from zero-inflated negative binomial regression models with offence rate as the dependent variable 
and period of observation within mirror image observation time (dichotomised into before treatment and during treatment), as the 
main independent variable of interest. Models took account of clustered before and during treatment data within individuals.  
a. Fully adjusted models are adjusted for urban residence, salary presence, employment status, and unemployment benefit 
receipt.  
 
 
